SEATTLE, March 5 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. , today announced that executives will present an overview of the company at two March investor conferences:
http://www.wsw.com/webcast/in6/trbn/
About Trubion
Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain polypeptide protein, or SMIPtm, therapeutics, and are designed using its custom drug assembly technology. Trubion's lead product candidate, TRU-015, has completed a Phase 2b clinical trial for the treatment of rheumatoid arthritis, and is also in development under the Wyeth collaboration for the treatment of non-Hodgkin's lymphoma, Systemic Lupus Erythematosus and other undisclosed indications.
Trubion's proprietary product candidate, TRU-016, is a novel CD37-targeted therapy for the treatment of B-cell malignancies currently in Phase 1 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: investors.trubion.com.
Forward-Looking Statements
Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to, those related to the company's future clinical development programs and the timing thereof, the company's expected financial and operating results, future clinical development plans, the details of the clinical trials and the results and timing thereof, and the timing of regulatory applications and action. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the company's Wyeth collaboration, including Wyeth's control over development timelines, and such other risks as identified in the company's quarterly report on Form 10-Q for the period ended Sept. 30, 2007, and from time to time in other reports filed by Trubion with the U.S. Securities and Exchange Commission. These reports are available on the Investors page of the company's corporate Web site at http://www.trubion.com. Trubion undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.
jdenike@trubion.comjmoede@wagged.com
CONTACT: Jim DeNike, Senior Director, Corporate Communications of Trubion
Pharmaceuticals, Inc., +1-206-838-0500, jdenike@trubion.com; or Jenny
Moede, Senior Vice President of Waggener Edstrom Worldwide Healthcare,
+1-503-443-7000, jmoede@wagged.com, for Trubion Pharmaceuticals, Inc.
Web site: http://www.trubion.com/
http://www.wsw.com/webcast/in6/trbn/
